Form 4: Amylyx Pharmaceuticals Co-CEO Joshua Cohen Reports Acquisition of Shares and Stock Options
SEC Form 4 Filing
Joshua Cohen, Co-CEO of Amylyx Pharmaceuticals, reports acquiring shares and stock options in the company.
Summary
- On March 6, 2025, Joshua B. Cohen, Co-CEO of Amylyx Pharmaceuticals, reported acquiring 180,118 shares of common stock and 270,177 stock options.
- The common stock was acquired through a restricted stock unit (RSU) award.
- The RSUs vest in four equal annual installments starting March 1, 2026, contingent upon continued service.
- The stock options have an exercise price of $3.61 and also vest over time, with 25% vesting on March 1, 2026, and the remainder vesting monthly over the subsequent 36 months, subject to continued service.
- Following these transactions, Cohen directly owns 3,376,770 shares of common stock and 270,177 stock options.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard regulatory filing detailing stock transactions by a company executive. The acquisition of shares and options could be seen as a positive signal, but it's not overwhelmingly so.
Positives
- The acquisition of shares and stock options by the Co-CEO could be interpreted as a sign of confidence in the company's future prospects.
- The vesting schedules for both the RSUs and stock options incentivize continued service and commitment from the Co-CEO.
Future Outlook
The vesting schedules for the RSUs and stock options suggest a long-term commitment from the Co-CEO to the company.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors for insights into management's perspective on the company's value and future prospects.
Stakeholder Impact
- The reported transactions could have a minor positive impact on shareholder sentiment, as they indicate confidence from a key executive.
- The vesting schedules incentivize the Co-CEO to remain with the company, which benefits employees and other stakeholders.
Key Dates
| Date | Description |
|---|---|
| 03/06/2025 | Date of transaction: Acquisition of common stock and stock options. |
| 03/01/2026 | First vesting date for both RSUs and 25% of stock options. |
| 03/05/2035 | Expiration date for the stock options. |
| 03/10/2025 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.